Login to Your Account



J.P. MORGAN 2015

Pharmacyclics' Imbruvica to hit blockbuster status this year, says CEO

By Jennifer Boggs
Staff Writer

Tuesday, January 13, 2015

Shares of Pharmacyclics Inc. jumped 11.4 percent in afterhours trading Monday following a lively afternoon presentation during which the firm told attendees of the J.P. Morgan Healthcare Conference that it expected cancer drug Imbruvica to hit blockbuster status in 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription